Oppenheimer Starts TherapeuticsMD (TXMD) at Outperform

November 21, 2016 5:03 PM EST
Get Alerts TXMD Hot Sheet
Price: $6.16 --0%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade TXMD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Oppenheimer initiates coverage on TherapeuticsMD (NYSE: TXMD) with a Outperform rating and a price target of $12.00.

Analyst Jay Olson commented, "We initiate coverage of TherapeuticsMD (TXMD) with an Outperform rating and a $12 price target based on the potential to successfully penetrate and expand the market for treatment of menopausal symptoms with two unique wholly owned products (Yuvvexy and TX-001HR) while an existing prenatal supplement business provides a foundation. These two new TXMD products are well differentiated and could provide unique benefits to women that are not available through existing treatments for menopausal women’s health."

For an analyst ratings summary and ratings history on TherapeuticsMD click here. For more ratings news on TherapeuticsMD click here.

Shares of TherapeuticsMD closed at $6.88 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Add Your Comment